In Brief
Refine Search
Biotechnology
US gene therapy company Voyager Therapeutics said today that Pfizer has exercised its option to license a next-generation capsid generated by Voyager’s TRACER capsid discovery platform in accordance with the agreement announced in October last year. 4 October 2022
Pharmaceutical
Pharnext has executed a financing agreement with Néovacs for around 21 million euros ($21 million), to help develop PXT3003 for Charcot-Marie-Tooth disease type 1A. 4 October 2022
Biotechnology
The US District Court for the Northern District of California has issued an order sustaining a jury verdict in favor of Plexxikon (the US subsidiary of Japan’s Daiichi Sankyo) on its claim that the US unit of Swiss pharma giant Novartis’ BRAF inhibitor Tafinlar (dabrafenib) infringes Plexxikon's US Patents 9,469,640 and 9,844.539. 3 October 2022
Biotechnology
Denmark-based SNIPR Biome has announced that its patent portfolio covering the use of CRISPR/Cas systems to edit prokaryotes is now available for academic and non-profit research use without a written license. 3 October 2022
Generics
UK provider of niche generic and branded specialty pharmaceuticals Aspire Pharma says it has completed its acquisition of privately-held Morningside Pharmaceuticals (Loughborough), Morningside Healthcare (Leicester) and Morningside Healthcare (India). 3 October 2022
Generics
The Court of Appeals for the Federal Circuit ruled in favor of Merck & Co in a patent challenge brought by Mylan Pharmaceuticals (now Viatris) related to sitagliptin dihydrogen phosphate, an active ingredient in Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride) and Janumet XR (sitagliptin and metformin hydrochloride extended-release). 30 September 2022
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma and Swiss market expansion services provider DKSH have entered into an agreement to bring therapeutic products for skin conditions and thrombosis to patients across Asia. 29 September 2022
Pharmaceutical
Transpire Bio, a USA-based developer of inhaled therapeutics for pulmonary and systemic diseases, today announced a second agreement with Sweden’s Recipharm to develop TRB-3 and TRB-4, inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease (COPD). 29 September 2022
Biotechnology
Pfizer and BioNTech have completed a submission to the European Medicines Agency to broaden the label for Comirnaty, to include a booster dose for children aged five to eleven. 29 September 2022
Biotechnology
In the USA, Vertex Pharmaceuticals and CRISPR Therapeutics have been granted a rolling review for their sickle cell disease (SCD) candidate exagamglogene autotemcel (exa-cel). 28 September 2022
Pharmaceutical
Ahmedabad, India-based Torrent Pharmaceuticals has agreed to buy fellow India-based medicinal dermatology company Curatio Health Care for 2,000 crores rupees ($245.22 million), the company said in a stock exchange filing on Tuesday. 27 September 2022
Pharmaceutical
Canada’s Bausch Health and India’s Glenmark Pharmaceuticals have received approval for Ryaltris (olopatadine hydrochloride/mometasone furoate) in Canada. 26 September 2022
Biosimilars
Adding to the roll out of their biosimilar to AbbVie’s mega blockbuster drug Humira (adalimumab), Icelandic firm Alvotech and German partner STADA Arzneimittel today announced the launch of Hukyndra in Switzerland. 22 September 2022
Biotechnology
Marketed by AstraZeneca and Merck & Co, cancer drug Lynparza (olaparib) has now been approved in China for an additional indication. 22 September 2022
Biotechnology
Roivant has filed a form S-3 with the US Securities and Exchange Commission (SEC), registering several prospectuses offering shares worth a total of $1 billion. 20 September 2022
Biotechnology
French specialty vaccine company Valneva and Germany-based IDT Biologika have agreed to terminate their collaboration following the delivery of inactivated COVID-19 bulk vaccine to Valneva, and considering the current order levels and existing inventories. 19 September 2022
Pharmaceutical
The European Commission has approved, under the European Union Merger Regulation, the acquisition of Norgine Europe, together with its subsidiaries (Norgine Group) of the Netherlands by the USA’s Goldman Sachs Group. 16 September 2022
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) today recommended converting the conditional marketing authorizations of the COVID-19 vaccines Comirnaty (from BioNTech and Pfizer’s vaccine) and Spikevax (Moderna’s vaccine) into standard marketing authorizations. 16 September 2022
Biotechnology
BRIEF—Positive Phase III results reinforce potential benefit of Opdivo in earlier stages of melanoma
The Phase III CheckMate -76K trial evaluating Opdivo (nivolumab) in the adjuvant setting in completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo at a pre-specified interim analysis. 15 September 2022
Biotechnology
Carver Biosciences, a Boston, USA-based biotech focused on the development of CRISPR/Cas13 antivirals, today announced the closure of a $3 million seed round of financing led by Khosla Ventures. 15 September 2022
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
San Diego-based Cidara Therapeutics, a biotech using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, has entered into a securities purchase agreement with certain investors to raise up to around $105 million. 21 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
Eli Lilly is not resting on its laurels when it comes to the fast-growing field of obesity treatments, an area in which it is already a leader. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
San Diego-based Valora Therapeutics, a biotech that boasts of having a novel approach to immunotherapy, has announced the successful closing of a $30 million seed funding round. 21 November 2024
Biotechnology
Astellas Pharma has been hit by bad news from the US Food and Drug Administration, which will not currently approve the firm’s request to supplement the label for Izervay (avacincaptad pegol). 21 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
Sage Therapeutics will down tools on its dalzanemdor program, after the Phase II DIMENSION trial missed both primary and secondary endpoints. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Biotechnology
HCW Biologics has announced a worldwide licensing agreement with WY Biotech to develop and commercialize one of its preclinical immunotherapy candidates. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
US clinical-stage biotech Vyriad has entered into a strategic collaboration with Swiss pharma giant Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies. 21 November 2024
Biotechnology
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. 20 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze